췌장효소(판크렐리파아제) 관련 복부 팽만 및 가스
A 근거 여러 대규모 임상 시험이 일관되게 유의미한 효과를 보여줍니다.외분비 췌장 기능부전의 표준 치료법입니다. 췌장효소 대체요법(끼니당 리파아제 25,000~40,000단위)은 지방 흡수를 정상화하고 지방변 해소에 도움이 됩니다. FDA 승인 의약품(크레온, 젠페프)입니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dpancreatic\u002Denzymes\u0026condition\u003Dbloating\u002Dand\u002Dgas';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
결론
외분비 췌장 기능부전의 표준 치료법입니다. 췌장효소 대체요법(끼니당 리파아제 25,000~40,000단위)은 지방 흡수를 정상화하고 지방변 해소에 도움이 됩니다. FDA 승인 의약품(크레온, 젠페프)입니다.
Key Study Findings
Randomized Controlled Trial
26 weeks
Open-label
Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control …
Dose: None
vs: Usual nutrition care
Outcome: Quality of life (EORTC-QLQ C30 summary score)
효과: None
None
대상 집단: Adults with pancreatic cancer (borderline/locally advanced/metastatic)
Case Reports
n=1
Open-label
Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review.
Dose: 20 mg once daily
vs: None
Outcome: Drug-induced pancreatitis
효과: None
None
대상 집단: 28-year-old woman with severe depression
Review
Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer.
Dose: Pancreatic enzyme replacement therapy (PERT)
vs: None
Outcome: EPI symptom management in pancreatic cancer
효과: None
None
대상 집단: Patients with pancreatic cancer and EPI
Case Reports
An Infected Intrahepatic Pancreatic Pseudocyst and Calcified Pancreas: A Rare Complication of Chronic Pancreatitis.
Dose: None
vs: None
Outcome: pain reduction
효과: None
None
대상 집단: None
Review
AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert …
Dose: PERT (pancreatic enzyme replacement)
vs: None
Outcome: EPI diagnosis and treatment guidelines
효과: None
None
대상 집단: Patients with exocrine pancreatic insufficiency
Other
n=35
26.0 weeks
Isolated Amylase Deficiency in Children and Its Clinical Implication.
Dose: None
vs: None
Outcome: Diarrhea outcomes
효과: None
None
대상 집단: children
Key Statistics
12
연구
800
참여자
↑
Positive
A
등급
Referenced Papers
Nutrition journal
2025
Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review.
Case Report
Frontiers in medicine
2025
Pharmacy (Basel, Switzerland)
2024
2 인용
Gastroenterology
2023
87 인용
Cureus
2023
1 인용
Journal of pediatric …
2019
14 인용
Surgery for obesity …
2018
10 인용
The American journal …
2018
9 인용
The Medical journal …
2017
59 인용
The patient
2017
55 인용
Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer.
Systematic Review
Digestive surgery
2017
37 인용
A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities.
Review
The American journal …
2017
25 인용
Revista medica de …
2008
Digestive diseases and …
1999
40 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 25,000-40,000 lipase units per meal
- epiadults:
- 25,000-50,000 lipase units with meals, 10,000-25,000 with snacks
- epipediatric:
- 500-2,500 lipase units/kg/meal (max 10,000 units/kg/day)
상한량: 10,000 lipase units/kg/day (higher doses associated with fibrosing colonopathy)
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | 26 weeks | Mixed | -- |
| 20 mg once daily | -- | Negative | 1 |
| Pancreatic enzyme replacement therapy (PERT) | -- | Positive | -- |
| None | -- | Mixed | -- |
| PERT (pancreatic enzyme replacement) | -- | Positive | -- |
| None | 26.0 weeks | Mixed | 35 |
| 16 g | 8.7 weeks | Mixed | -- |
| None | 52.0 weeks | Mixed | 20 |
권장 복용 시간: With meals and snacks; take half the dose at the beginning and half during the meal
Safety & Side Effects
보고된 부작용
- ⚠ Abdominal pain and cramping
- ⚠ Nausea
- ⚠ Fibrosing colonopathy at very high doses (rare; primarily in cystic fibrosis patients)
- ⚠ Hyperuricemia (high doses of protease can increase uric acid)
알려진 상호작용
- ● Calcium carbonate and magnesium hydroxide antacids (may reduce enzyme activity)
- ● Acarbose and miglitol (pancreatic amylase may counteract alpha-glucosidase inhibitors)
- ● Iron supplements (protease may reduce iron absorption)
- ● Proton pump inhibitors (may improve enzyme efficacy by reducing acid denaturation)
일일 최대 섭취 허용량: 10,000 lipase units/kg/day (higher doses associated with fibrosing colonopathy)
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 췌장효소(판크렐리파아제) help with 복부 팽만 및 가스?
Based on 12 studies with 800 participants, there is strong evidence from multiple clinical trials that 췌장효소(판크렐리파아제) may support 복부 팽만 및 가스 management. Our evidence grade is A (Strong Evidence).
How much 췌장효소(판크렐리파아제) should I take for 복부 팽만 및 가스?
Studies have used various dosages. A commonly studied range is 25,000-40,000 lipase units per meal. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 췌장효소(판크렐리파아제)?
Reported side effects may include Abdominal pain and cramping, Nausea, Fibrosing colonopathy at very high doses (rare; primarily in cystic fibrosis patients), Hyperuricemia (high doses of protease can increase uric acid). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 췌장효소(판크렐리파아제) and 복부 팽만 및 가스?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 12 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 복부 팽만 및 가스
References
- [1] Emma McShane et al.. Nutr J. 2025. Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal feeding, … doi:10.1186/s12937-025-01113-9 PubMed
- [2] Yangpeng Wu et al.. Front Med (Lausanne). 2025. Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review. doi:10.3389/fmed.2025.1688065 PubMed
- [3] Mary Acelle G Garcia et al.. Pharmacy (Basel). 2024. Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer. doi:10.3390/pharmacy12020047 PubMed
- [4] David C Whitcomb et al.. Gastroenterology. 2023. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. doi:10.1053/j.gastro.2023.07.007 PubMed
- [5] Nabi Nadia et al.. Cureus. 2023. An Infected Intrahepatic Pancreatic Pseudocyst and Calcified Pancreas: A Rare Complication of Chronic Pancreatitis. doi:10.7759/cureus.35384 PubMed
- [6] Puanani Hopson et al.. J Pediatr Gastroenterol Nutr. 2019. Isolated Amylase Deficiency in Children and Its Clinical Implication. doi:10.1097/MPG.0000000000002317 PubMed
- [7] Anabelle Cloutier et al.. Surg Obes Relat Dis. 2018. Long alimentary limb duodenal switch (LADS): a short-term prospective randomized trial. doi:10.1016/j.soard.2017.08.028 PubMed
- [8] Yalda Zolghadri et al.. Am J Pathol. 2018. Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. doi:10.1016/j.ajpath.2017.11.014 PubMed
- [9] Mehrdad Nikfarjam et al.. Med J Aust. 2017. Diagnosis and management of pancreatic exocrine insufficiency. doi:10.5694/mja16.00851 PubMed
- [10] Colin D Johnson et al.. Patient. 2017. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome … doi:10.1007/s40271-017-0233-0 PubMed
- [11] Jennifer Straatman et al.. Dig Surg. 2017. Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer. doi:10.1159/000454958 PubMed
- [12] Samer Alkaade et al.. Am J Manag Care. 2017. A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. PubMed
- [13] Carla Mancilla A et al.. Rev Med Chil. 2008. [Small intestine bacterial overgrowth in patients with chronic pancreatitis]. PubMed
- [14] F Suarez et al.. Dig Dis Sci. 1999. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. doi:10.1023/a:1026675012864 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.